*Fixed-dose combination, formerly known as G/P, contains glecaprevir and AbbVie's NS5A Inhibitor, pibrentasvir. Marketed ex U.S. as MAVIRET.**VIEKIRA PAK and TECHNIVIE are no longer marketed in the U.S.; VIEKIRAX is still sold primarily in select jurisdictions where MAVYRET is not yet approved.